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nregulated FGF signaling affects endochondral ossi-
ﬁcation and long bone growth, causing several genetic
forms of human dwarﬁsm. One major mechanism
by which FGFs regulate endochondral bone growth is through
their inhibitory effect on chondrocyte proliferation. Because
mice with targeted mutations of the retinoblastoma (Rb)-
related proteins p107 and p130 present severe endochondral
bone defects with excessive chondrocyte proliferation,
we have investigated the role of the Rb family of cell cycle
regulators in the FGF response. Using a chondrocyte cell
line, we found that FGF induced a rapid dephosphorylation
of all three proteins of the Rb family (pRb, p107, and p130)
and a blockade of the cells in the G1 phase of the cell
cycle. This cell cycle block was reversed by inactivation of
Rb proteins with viral oncoproteins such as polyoma large
T (PyLT) antigen and Adenovirus E1A. Expression of a PyLT
mutant that efﬁciently binds pRb, but not p107 and p130,
U
 
allowed the cells to be growth inhibited by FGF, suggesting
that pRb itself is not involved in the FGF response. To invest-
igate more precisely the role of the individual Rb family
proteins in FGF-mediated growth inhibition, we used
chondrocyte micromass culture of limb bud cells isolated
from mice lacking Rb proteins individually or in combination.
Although wild-type as well as 
 
Rb
 
 
 
/
 
 
 
 chondrocytes were
similarly growth inhibited by FGF, chondrocytes null for
p107 and p130 did not respond to FGF. Furthermore, FGF
treatment of metatarsal bone rudiments obtained from
 
p107
 
 
 
/
 
 
 
;
 
p130
 
 
 
/
 
 
 
 embryos failed to inhibit proliferation of
growth plate chondrocytes, whereas rudiments from p107-
null or p130-null embryos showed only a slight inhibition
of growth. Our ﬁndings indicate that p107 and p130, but
not pRb, are critical effectors of FGF-mediated growth inhi-
bition in chondrocytes.
 
Introduction
 
Signaling through FGF receptors (FGFR)* plays a major
role in development by eliciting a variety of responses in
FGF-targeted cells, ranging from induction of proliferation
and differentiation to growth inhibition. FGF signaling
plays a role in bone development and affects the process of
endochondral ossification, which accounts for the formation
of most of the skeletal bones (Goldfarb, 1996; De Luca and
Baron, 1999; Karsenty, 1999; Powers et al., 2000). In endo-
chondral ossification, the initial formation of a cartilage
anlage by the condensation of mesenchymal stem cells is fol-
lowed by proliferation and differentiation of chondrocytes
that provide the template for bone formation. Considerable
evidence from human and mouse genetics indicates that long-
itudinal bone growth is regulated by FGF signaling. Gain of
function mutations in FGFR3, which is expressed in growth
plate chondrocytes, are responsible for several forms of hu-
man dwarfism including achondroplasia, whereas in mice,
knockout of the 
 
FGFR3
 
 gene causes overgrown and de-
formed long bones and unregulated FGF signaling produces
a variety of chondrodysplasias (Deng et al., 1996; Naski et
al., 1996; Webster and Donoghue, 1997; Karsenty, 1999).
In line with the genetic evidence that excessive FGF sig-
naling impairs long bone growth (Naski and Ornitz, 1998),
we previously showed that FGF signaling inhibited chon-
drocyte proliferation in vitro and in vivo (Sahni et al.,
1999), suggesting that one major mechanism by which
FGFs regulate bone development is through their inhibitory
effect on chondrocyte proliferation. We also showed,
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through the use of 
 
Stat1
 
 knockout mice, that this phenome-
non required the intervention of STATl, a signal transduc-
ing molecule originally identified in the interferon pathway
(Sahni et al., 1999). Furthermore, we showed that FGF sig-
naling induced chondrocyte apoptosis both in vitro and in
vivo, and this also required STAT1 function (Sahni et al.,
2001). Although FGF induces a proliferative arrest through
a STAT1-dependent process in chondrocytes, in most other
cell types FGFs elicit increased proliferation (Basilico and
Moscatelli, 1992). Presently, the basis for the FGF growth
inhibition of chondrocytes, versus the FGF-proliferative ef-
fect in most other cell types, is not defined.
To gain information on the mechanisms through which
FGF signaling induces growth arrest in chondrocytes, we
sought to identify other downstream effectors of FGF-medi-
ated growth inhibition. It had been previously shown that
mice with targeted inactivation of two members of the reti-
noblastoma (Rb) gene family, 
 
p107
 
 and 
 
p130
 
, died at birth
with developmental defects including defective endochon-
dral bone development and abnormally high levels of chon-
drocyte proliferation (Cobrinik et al., 1996). The Rb family
of pocket proteins includes three members (pRB, p107, and
p130) that are known to be major regulators of cell cycle
progression in essentially all cells and tissues (Ewen, 1998;
Mulligan and Jacks, 1998). In the active underphosphory-
lated form, the Rb family proteins bind the E2F family of
transcription factors, resulting in transcriptional inhibition
of many cell cycle progression and DNA synthesis genes. In-
activation of Rb family proteins by phosphorylation allows
freeing of E2Fs factors which then positively influence tran-
scription of cell cycle progression genes (Dyson, 1998).
We have investigated the hypothesis that the high levels of
chondrocyte proliferation observed in 
 
p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
 
 
 mu-
rine embryos could have been due, at least in part, to an im-
paired response to the growth-inhibitory effects of FGF
signaling. To this end, we have expressed in cultured
chondrocytes the adenovirus E1A (E1A) and polyoma large
T (PyLT)-Ag proteins, that are known to bind and inacti-
vate Rb proteins (Dyson et al., 1990; Classon and Dyson,
2001), and studied the response to FGF treatment of chon-
drocyte micromass cultures and cartilaginous bone rudi-
ments from 
 
pRb
 
, 
 
p130
 
, and 
 
p107
 
 knockout mouse embryos.
Here, we show that expression of E1A or PyLT in rat chon-
drosarcoma (RCS) chondrocytes produces cells that no
longer respond to FGF with growth inhibition. Experiments
with chondrocyte micromass cultures and bone rudiments
from mutant embryos further revealed that p107 and p130,
but not pRb, are required for the growth inhibitory effects of
FGF. Our data demonstrate that p107 and p130 are essen-
tial downstream mediators of the FGF-induced growth ar-
rest of chondrocytes.
 
Results
 
FGF-induced growth inhibition of RCS cells is associated 
with dephosphorylation of Rb family proteins
 
Treatment of RCS chondrocytes with FGF-1 induces a po-
tent growth inhibitory response (Sahni et al., 1999; see Fig.
2 A). FACScan™ analysis revealed that FGF-1 treatment of
RCS cells promotes an accumulation of cells in the G0/G1
phase of the cell cycle (Fig. 1 A). Because Rb proteins consti-
tute major regulators of the G1 to S phase transition (Ewen,
1998), we examined the phosphorylation status of these pro-
teins as a read-out of their activities. This was done by West-
ern blotting and immunodetection of the different phos-
phorylated forms of the Rb proteins, based on their
characteristic electrophoretic mobilities. Treatment of RCS
cells with FGF-1 for different times over a 24-h period
showed that all three Rb family members (pRb, p107, and
p130) became dephosphorylated after FGF treatment (Fig.
1 B). The kinetics of dephosphorylation was rapid, particu-
larly in the case of p107, which is totally dephosphorylated
as early as 9 h after FGF treatment. After 18 h of FGF treat-
ment, all three Rb proteins were mainly present in their un-
derphosphorylated forms. The G1 arrest induced by FGF-1
in RCS chondrocytes is reversible. Resumption of cell prolif-
eration is accompanied by an increase in Rb proteins phos-
phorylation (unpublished data).
Because Rb proteins phosphorylation is mediated by Cdk,
whose activity in turn is regulated by several Cdk inhibitors,
we measured the expression of several members of the Cip/
Kip and Ink4 families of Cdk inhibitors in RCS cells after
FGF treatment. As previously shown by us and others
(Sahni et al., 1999; Aikawa et al., 2001), the expression of
p21 was up-regulated rather rapidly after FGF addition. On
the other hand, expression of p27 and p57 was increased
slightly and at later times. No changes in the expression of
p16 and p18 were detected (Fig. 1 C).
 
Inactivation of Rb family proteins abolishes 
FGF-mediated growth inhibition of RCS cells
 
The rapid dephosphorylation of Rb proteins after FGF treat-
ment suggested that their dephosphorylation could be a cause
and not an effect of the growth arrest. To investigate whether
the function of Rb proteins was required for FGF-induced
growth arrest of RCS cells, we expressed by retroviral-medi-
ated gene transfer two viral oncoproteins, PyLT antigen and
E1A, which are known to interact directly with Rb proteins,
and as a consequence, inactivate their function (Classon and
Dyson, 2001). We measured the frequency of DNA-synthe-
sizing cells by counting cells that had incorporated BrdU from
18 to 24 h after FGF treatment, and compared parental RCS
cells with RCS that stably expressed PyLT or E1A. As shown
in Fig. 2 A, expression of PyLT or E1A into RCS cells led to a
marked decrease in FGF-induced growth inhibition in com-
parison with wild-type or vector-transfected RCS cells. In the
case of PyLT-expressing RCS cells, we further confirmed that
the early effects of FGF signaling were unaffected by the in-
troduction of PyLT protein as judged by FGF-induced tyro-
sine phosphorylation of FGFR3 (the major FGF receptor ex-
pressed in these cells) as well as tyrosine phosphorylation of
several endogenous proteins (unpublished data).
To confirm that the Rb family proteins binding ability of
PyLT or E1A was implicated in the loss of FGF response, we
used well defined mutants of these proteins carrying either a
specific deletion or a point mutation of the Rb binding site
(PyLT-
 
 
 
141–158 and E1A-12S.928, respectively; Wang et
al., 1993; Pilon et al., 1996), and having impaired binding to
each of the pRb family proteins. As shown in Fig. 2 A, expres-
sion of these mutants did not affect the growth inhibitory re- 
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sponse observed in FGF-treated RCS cells, indicating that in-
activation of Rb proteins by PyLT or E1A was responsible for
the lack of FGF response. To exclude the possibility that the
effect produced by the expression of PyLT and E1A could be
triggered by the introduction of any oncogene into RCS cells,
we also expressed another unrelated oncogene, an activated
form of H-ras (Dotto et al., 1985), in these cells. Proliferation
of v-H-ras–expressing RCS cells was inhibited by FGF to the
same extent as RCS-treated cells (unpublished data).
Next, we wanted to exclude the possibility that PyLT- or
E1A-expressing RCS cells were resistant to all growth inhib-
itory signals. Dexamethasone, a glucocorticoid that has been
shown to inhibit chondrocyte growth both in vitro and in
vivo (Jux et al., 1998; Klaus et al., 2000), induced a dose-
dependent inhibition of proliferation of RCS cells (Fig. 2
B). Importantly, PyLT-expressing RCS cells treated with
dexamethasone were comparably growth inhibited. Thus,
the expression of PyLT does not make RCS cells refractory
to all growth inhibitory signals.
 
Inactivation of pRb is not sufficient to block
FGF-mediated growth inhibition of RCS cells
 
As discussed in the Introduction, studies of knockout mice
have indicated an important role of the pRb-related proteins
(p107 and p130) during chondrogenesis and particularly in
the growth control of chondrocytes. To determine whether
pRb, p107, and p130 equally contributed to FGF-induced
growth arrest, we took advantage of a PyLT deletion mutant
(PyLT-
 
 
 
256–272) that has been described to possess a re-
duced ability to bind p107, while maintaining both the po-
tential to interact with pRb and to immortalize fibroblasts in
vitro (Pilon et al., 1996). Because the binding characteristics
of this mutant were determined in vitro using recombinant
proteins, we first asked whether this PyLT mutant behaved
similarly when expressed in cells. We expressed PyLT-
 
 
 
256–
272 in RCS cells and examined the interaction of this mutant
with Rb proteins in comparison to wild-type PyLT in coim-
munoprecipitation experiments. For these experiments as
well as for the proliferation experiments, we selected clones
Figure 1. FGF induces G1 arrest of 
RCS cells and dephosphorylation of Rb 
proteins. (A) FACScan™ analysis of 
propidium iodide–labeled cells, treated 
with 10 ng/ml FGF-1 (or left untreated) for 
24 h. Percentage of cells in each phase 
of the cell cycle is indicated. (B) Time 
course analysis (Western blot) of the 
phosphorylation status of Rb protein 
family members (pRb, p107, and p130) 
after FGF treatment (10 ng/ml) of RCS cells. 
Black or white arrows indicate the position 
of the hyper- or hypophosphorylated 
forms of Rb proteins, respectively. (C) 
Western blot analysis showing the 
expression levels of Cdk inhibitors of 
the Cip/Kip (p21, p27, and p57) and Ink4 
(p16 and p18) families, after 0, 12, and 
24 h of FGF treatment. Equal amount of 
protein loading was confirmed by Grb2 
immunodetection. 
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expressing similar amounts of PyLT and PyLT-
 
 
 
256–272
proteins, as judged by Western blot analysis (Fig. 3 B, see in-
set). As shown in Fig. 3 A, immunoprecipitation of both
p107 and p130 revealed a strong reduction in the amount of
PyLT-
 
 
 
256–272 in the immune complexes (Fig. 3 A, lanes
3), in comparison with wild-type PyLT (Fig. 3 A, lanes 2).
On the other hand, immunoprecipitation of pRb produced
bands of similar intensity for both wild-type and mutant
PyLT. Thus, these results were in agreement with the pub-
lished data regarding the pRb/p107 binding abilities of the
mutant PyLT-
 
 
 
256–272 protein (Pilon et al., 1996). They
also revealed that the ability of PyLT-
 
 
 
256–272 protein to
interact with p130 is affected in parallel with its ability to
bind p107, a finding perhaps predictable given the extensive
protein sequence similarities between p130 and p107.
BrdU incorporation assays (Fig. 3 B) showed that PyLT-
 
 
 
256–272–expressing RCS cells were growth-inhibited by
FGF treatment in a dose-dependent manner, similarly to con-
trol RCS cells, whereas wild-type PyLT-expressing RCS cells
were consistently resistant to FGF growth inhibition. The in-
ability of a PyLT mutant that can bind pRb, but not p107
and p130, to block the FGF response indicates that inactiva-
tion of pRb alone is not sufficient to interfere with FGF-
mediated growth inhibition of RCS cells, and that the FGF
response is likely mediated through p107 and p130 function.
 
p107 and p130 mediate the FGF-induced growth arrest 
in micromass chondrocytes
 
Although the above analyses suggested the importance of
p107 and p130 to FGF-induced arrest in RCS cells, they did
not exclude the possibility that any one of the Rb family
proteins was sufficient to mediate the FGF response. More-
over, because RCS are tumor cells, it was of interest to de-
fine the role of each of the Rb family proteins in the FGF
response in nontransformed cells. Thus, to define the im-
portance of p107, p130, or pRb to FGF-induced growth
Figure 3. RCS cells expressing a mutant PyLT protein that does 
not bind efficiently to p107 and p130 are growth inhibited by FGF. 
(A) Analysis of the interactions between Rb protein family members 
and PyLT versus PyLT 256–272 deletion mutant in RCS cells by 
coimmunoprecipitation. Rb protein family members were individually 
immunoprecipitated from lysates of RCS cells (lane 1), PyLT-
expressing cells (lane 2), and PyLT 256–272–expressing cells (lane 3). 
After SDS-PAGE and Western blotting, membranes were probed 
with an anti-PyLT mAb (top panels). The same nitrocellulose 
membranes were stripped and reprobed with specific antibodies 
against pRb proteins (bottom panels). Black arrows indicate the po-
sition of wild-type PyLT (slower migrating) and mutant PyLT_256–272 
(faster migrating). The asterisk indicates a nonspecific contaminant 
immunoprecipitated by the anti-pRb antibody and recognized by 
PyLT antibody. (B) BrdU incorporation assay of control RCS cells 
and RCS expressing either wild-type or mutant (PyLT_256–272) 
PyLT treated for 24 h with increasing concentration of FGF. 
(inset) Western blot analysis of the expression level of wild-type 
and mutant PyLT proteins in the cells used for these experiments.
Figure 2. Functional inactivation of Rb proteins interferes with 
FGF-induced growth arrest. (A) BrdU incorporation assay of FGF-
treated (10 ng/ml) or untreated RCS cells expressing either PyLT, 
E1A, or mutant of these proteins defective in Rb family proteins 
interaction (PYLT 141–158, E1A-12S.928). (B) BrdU incorporation 
assay of dexamethasone-treated parental and PyLT-expressing RCS 
cells. Note that proliferation assays presented in Figs. 2 and 3 were 
conducted at least three times and gave similar results. Quantification 
was evaluated by counting the number of BrdU-positive cells 
among the total number of cells (200–400 cells) from several 
representative fields ( SD). 
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arrest, we prepared primary chondrocytes that specifically
lacked those proteins. The chondrocytes were obtained us-
ing high density micromass cultures derived from prechon-
drogenic limb bud mesenchyme from embryos of different
 
p107
 
, 
 
p130
 
, and 
 
Rb
 
 genotypes. These mesenchyme cultures
form multiple condensations in which both chondrogenic
differentiation and chondrocyte proliferation take place (Ah-
rens et al., 1979).
The initial behavior of micromass cultures of the different
genotypes was consistent with that previously described (Ah-
rens et al., 1979). The cells initially formed a densely packed
layer, then formed foci, and the size of these foci increased
with time (Fig. 4 D). By day three, chondrogenesis had
taken place within the foci, as detected by Alcian blue stain-
ing of the cartilage matrix and by collagen II and FGFR3
protein expression (Fig. 4 and data not shown). This is in
keeping with the finding that early steps of chondrogenic
differentiation were not blocked in p107/p130-deficient
embryos (Rossi et al., 2002). Furthermore, no differences in
FGFR3 expression were found among the different geno-
types (unpublished data).
To determine the effect of FGF on chondrocytes prolifer-
ation, day 3 cultures were treated with FGF for 24 h, and
BrdU was added over the last 2 h. The cultures were stained
simultaneously with an antibody against collagen II (to iden-
tify chondrocytes) and with an antibody against BrdU (to
identify S phase cells), and the proportion of BrdU-positive
chondrocytes was determined by confocal microscopy. This
technique allows individual chondrocytes within the carti-
lage nodules to be examined by focusing on a single plane.
In wild-type cultures, FGF induced a 50% decrease in
chondrocyte BrdU incorporation, with chondrocytes in the
middle of the foci responding more strongly to FGF than
those at the edge (Fig. 5). Interestingly, 
 
Rb
 
 
 
/
 
 
 
 chondrocytes
responded to FGF to the same extent as wild-type chondro-
cytes (Fig. 5), indicating that pRb was not needed for FGF
to inhibit proliferation. Similarly, 
 
p107
 
 
 
/
 
 
 
;
 
p130
 
 
 
/
 
 
 
 chon-
drocytes underwent an FGF-induced growth arrest (Fig. 5),
implying that a single wild-type p
 
107
 
 and p
 
130
 
 allele is suf-
ficient for the full FGF response. In contrast, 
 
p107
 
 
 
/
 
 
 
;
p130
 
 
 
/
 
 
 
 chondrocytes displayed a partial inhibition (Fig. 5),
suggesting that p130 can mediate, at least in part, the FGF
growth arrest response. Strikingly, 
 
p107/p130
 
 double mu-
tants chondrocytes did not arrest in response to FGF. In-
deed, neither did 
 
p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
 
 
 
 
nor
 
 p107
 
 
 
/
 
 
 
 chondro-
cytes (Fig. 5), indicating that p107 was crucial to the
FGF-induced growth arrest in this system.
 
p107 and p130 mediate FGF-induced growth 
inhibition in mouse bone rudiments
 
Next, we sought to determine whether p107 and p130 were
needed for the FGF response not only in cultured chondro-
cytes, but also in chondrocytes that are within developing
bones that have a normal cartilage architecture. For this pur-
pose, we used organ culture of metatarsal bone rudiments of
mice with targeted 
 
p107
 
 and/or 
 
p130
 
 inactivation. In brief,
bone rudiments from E15 mouse embryos were isolated and
cultivated in vitro for 24 h and then treated with FGF-1 or
left untreated for an additional 24 h. BrdU was added to the
culture medium for the last 6 h. The rudiments were pro-
cessed for immunohistochemistry, and BrdU incorporation
was evaluated by immunostaining of the rudiment sections.
The frequency of chondrocytes incorporating BrdU in the
proliferative zone of untreated rudiments was similar (Fig. 6)
in all the different genotypes that we examined. Metatarsals
from double heterozygotes mice (
 
p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
 
 
) showed
strong inhibition of DNA synthesis upon FGF treatment
(Fig. 6), similar to that observed in wild-type bone rudiments
(not depicted). FGF treatment produced essentially no inhi-
bition of DNA synthesis in 
 
p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
 
 
 rudiments, and
a slight but reproducible decrease in 
 
p107
 
 
 
/
 
 
 
;p130
 
 
 
/
 
 
 
 rudi-
ments, similar to that observed in chondrocyte micromass
cultures. FGF treatment of bone rudiments from p107/p130-
null rudiments resulted in no inhibition in DNA synthesis,
and actually caused a small but reproducible increase in the
rate of proliferation (Fig. 6 B), suggesting that blocking the
growth inhibitory effects of FGF signaling in these cells could
perhaps unmask its growth stimulatory potential. These re-
sults show that in developing bone rudiments, removal of
p107 activity essentially abolishes chondrocyte growth inhibi-
tion by FGF, and that chondrocytes become completely resis-
Figure 4. Production of p107
 / ;p130
 /  and p107
 / ;p130
 /  
chondrocytes in high density micromass cultures. (A–F) Phase-contrast 
image of micromass cultures from p107
 / ;p130
 /  (A, C, and E) 
and p107
 / ;p130
 /  (B, D, and F) cultures at day 1 (A and B), day 3 
(C and D), and day 4 (E and F) after plating. (G and H) Alcian blue 
staining of chondrocyte foci in p107
 / ;p130
 /  (G) and p107
 / ;
p130
 /  (H) cultures 3 d after plating, and shown at lower magnifi-
cation than in A–F. Each blue spot represents a chondrocyte focus. 
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tant when p130 is also absent. pRb, which is not mutated in
these embryos, fails to compensate for the loss of p107 and
p130. Thus, p107 and p130 are the major mediators of FGF
growth inhibition in growth plate chondrocytes.
 
Discussion
 
The results described in this paper indicate that two mem-
bers of the Rb family of pocket proteins (p107 and p130),
but surprisingly not the prototype of the family (pRb), are
essential effectors of the FGF signal cascade in chondrocytes
that leads to inhibition of cell proliferation. Expression of vi-
ral proteins such as E1A and PyLT-Ag, which bind and in-
activate Rb proteins, essentially suppress the growth inhibi-
tory response of RCS chondrocytes to FGF. Not only was
this effect not manifested in cells expressing mutant forms of
PyLT and E1A incapable of binding to all Rb proteins, but
more specifically a PyLT mutant that is selectively impaired
in binding to p107 and p130, but not to pRb, was also inca-
pable of blocking the FGF response. Notably, the loss of Rb
family proteins’ function did not affect the response to other
growth inhibitory agents.
The most conclusive demonstration of the p107 and p130
role in mediating the FGF effect in cell proliferation was
provided by experiments with chondrocyte micromass cul-
tures or cartilaginous metatarsal bone rudiments from mu-
rine embryos with targeted mutations of 
 
pRb
 
, 
 
p107,
 
 and
 
p130
 
. Although the absence of pRb had no apparent effect
on the FGF response, the loss of either p107 or p130 re-
sulted in almost no inhibition of chondrocyte proliferation.
Chondrocytes lacking both p107 and p130 showed no
growth inhibition in response to FGF, and actually a small
but reproducible increase in the rate of proliferation. This
effect could be due to an “unmasking” of the growth stimu-
latory effects of FGF when growth inhibition is removed,
and is reminiscent of what we previously observed in bone
rudiments from 
 
STAT1
 
 knockout mice (Sahni et al., 1999).
Although our analysis indicates that pRb is dispensable for
FGF-induced growth arrest, it is difficult at this point to de-
termine whether p130 or p107 is the major mediator of the
FGF response. Although the experiments performed with
micromass chondrocytes seem to suggest that p107 plays the
major role, it is clear from the deregulated proliferation of
p107
 / ;p130
 /  but not p107
 / ;p130
 /  chondrocytes in
micromass and bone rudiments that p130 also mediates the
FGF growth inhibitory effect. These findings are consistent
with roles of p107 and p130 that were deduced from the
phenotype of p107- and p130-deficient mice. The original
investigation of p107 knockout mice showed only a subtle
bone phenotype (Cobrinik et al., 1996), and that chondro-
cyte proliferation was severely deregulated only in the p107/
p130-deficient growth plates. However, more recent studies
indicated that p107 was essential to chondrocyte prolifera-
tion control at early times during chondrogenesis, when
p130 expression is minimal (Rossi et al., 2002). This also
militates in favor of an overlapping, redundant role of p107
and p130 in chondrocyte proliferation. It is possible that the
micromass and bone rudiments organ culture conditions
make the chondrocytes less susceptible to FGF-mediated
growth inhibition, so that removal of either p130 or p107 is
Figure 5. Loss of p107 and p130 impairs FGF-induced growth 
arrest in micromass chondrocytes. (A) Day 3 micromass cultures of 
the indicated genotypes were treated with FGF or vehicle for 24 h, 
and allowed to incorporate BrdU over the final 2 h. Chondrocytes 
were stained with anti–collagen II and an FITC-conjugated secondary 
antibody (green), and with anti-BrdU and a Cy3-conjugated secondary 
antibody (red), and analyzed by confocal microscopy. (B) Quantifi-
cation of the percentage of BrdU( ) chondrocytes in a series of 
confocal sections from at least five foci for each genotype and each 
condition. Error bars represent SD of the percentages of BrdU( ) cells 
in each focus. Note that in FGF-treated wild-type (WT), Rb
 /  and 
p107
 / ;p130
 /  cultures, the majority of the BrdU( ) nuclei were 
at the periphery of the foci, and that growth inhibition was more 
substantial for cells within the cores of the foci. FGF arrests chondrocyte growth through p107 and p130 | Laplantine et al. 747
sufficient to almost abolish the effect of FGF treatment,
whereas loss of both is needed to substantially deregulate
proliferation in vivo. Furthermore, other factors may coun-
teract the action of FGF in vivo, which would have to be
completely blocked to produce a distinct phenotype.
Although further work will be needed to resolve this issue,
it is perhaps more interesting to ask why pRb does not seem
to participate in the FGF response of chondrocytes. pRb is
equally dephosphorylated in RCS cells upon FGF treat-
ment, but alone it does not seem to be capable of affecting
FGF-mediated growth inhibition. pRb may not be an im-
portant regulator of cell cycle progression in chondrocytes.
It has been long suspected that the function of the Rb family
proteins is overlapping, but also shows tissue specificity
(Lipinski and Jacks, 1999). The loss of all three Rb proteins
is necessary to fully immortalize fibroblasts (Dannenberg et
al., 2000; Sage et al., 2000), but loss of pRb alone is suffi-
cient to deregulate proliferation of liver, lens, neural, muscle,
and pituitary cells (Clarke et al., 1992; Jacks et al., 1992;
Lee et al., 1992). Similarly, the loss of pRb, but not of p107
or p130, inhibits late osteoblast differentiation in vitro
(Thomas et al., 2001). On the other hand, in the Ba/F3 he-
matopoietic cell line, cell cycle progression appears to be mainly
controlled by p130 (Hoshikawa et al., 1998). An alternative
hypothesis is that our results could reflect a more specific
role of p107 and p130 in the FGF response, such as if FGF
signaling targeted functions of p107 and/or p130 that are
not possessed by pRb. p107 and p130 are known to form
complexes with E2F4 and E2F5, whereas pRb preferentially
regulates E2F1, E2F2, and E2F3 (Sardet et al., 1995;
Dyson, 1998; Classon and Dyson, 2001). E2F/p107 and
p130 complexes bind specific DNA sequences and inhibit
the transcription of targeted genes (Hurford et al., 1997). It
is possible that FGF-mediated growth inhibition depends
strictly on the repression of specific genes, which would be
regulated by the E2F/p107 or p130 complexes. As another
possibility, the p107- and p130-dependent inhibition of
chondrocyte proliferation may depend upon the ability of
these proteins to directly bind and inhibit Cdk2 kinase, a
property that is not shared with pRb (Hannon et al., 1993;
Classon and Dyson, 2001).
A further issue that is raised by the current work is
whether the role of p107 and p130 in the FGF response is
linked to their roles in chondrocyte differentiation. Analy-
sis of p107
 / ;p130
 /  embryos clearly showed a block
to chondrocyte hypertrophic differentiation (Rossi et al.,
2002), and this defect was also observed in organ cultures of
the metatarsal rudiments, regardless of FGF treatment. Sim-
Figure 6. Absence of FGF-induced 
growth inhibition in bone rudiment 
chondrocytes lacking p107 and/or 
p130. Metatarsal bone rudiments from 
E15 embryos were isolated and culti-
vated in vitro for 48 h with or without 
FGF treatment (100 ng/ml for 24 h). 
BrdU was added during the last 6 h 
of the culture. After fixation, rudiments 
were processed for immunodetection 
of BrdU. Counterstaining with Alcian 
blue was done in order to stain the 
cartilage-specific sulfate proteoglycans 
present in the extracellular matrix. (A) 
Representative pictures of BrdU incor-
poration in the proliferative zone of 
the growth plate for the different geno-
types analyzed. R, reserve zone; P, 
proliferating zone; H, hypertrophic 
zone. (B) Quantification. Note that 
error bars in Fig. 6 B represent the SD 
calculated from at least six counts (percentage of cells positive 
for BrdU) of 80–160 cells each. Organ culture experiments were 
performed twice and gave similar results.748 The Journal of Cell Biology | Volume 158, Number 4, 2002
ilar to the in vivo situation, the appearance of hypertrophic
chondrocytes could be easily detected in p107
 / ;p130
 / 
rudiments as well as in p130
 / ;p107
 /  rudiments, but was
rarely detected in p107
 / ;p130
 /  rudiments and not de-
tected at all in rudiments from p107
 / ;p130
 /  embryos
(data not shown). As shown recently (Rossi et al., 2002), the
inhibition of chondrocyte differentiation observed in p130/
p107 knockout embryos could be due to the impaired ex-
pression of Cbfa 1, a transcription factor that is important
for chondrocyte hypertrophic differentiation (Inada et al.,
1999; Kim et al., 1999; Takeda et al., 2001). Whether this is
in turn related to the resistance of these cells to FGF treat-
ment is currently unclear. The question of whether FGF
treatment accelerates or inhibits chondrocyte terminal dif-
ferentiation and whether this effect may require cell cycle ar-
rest and the intervention of the Rb proteins is presently un-
dergoing investigation.
Finally, our results are consistent with a relatively simple
mechanism by which FGF would mediate growth inhibition
of chondrocytes. FGF treatment could, through the activa-
tion of STAT1, induce the expression of Cdk inhibitors,
leading to inhibition of Rb family proteins phosphorylation.
Indeed, it was previously shown that p21 is induced by FGF
treatment in chondrocytes (Sahni et al., 1999; Aikawa et al.,
2001). As shown here, the expression of p27 and p57 is also
induced by FGF in chondrocytes, but weakly and with de-
layed kinetics. On the other hand, we found that p21 is also
strongly induced by FGF in many cell types where its major
biological effect is growth stimulation, and not growth inhi-
bition. Furthermore, p21
 /  mice have not been reported as
having a clear bone phenotype (Deng et al., 1995), and p21
deletion only partially reduced the ability of FGF to inhibit
chondrocyte proliferation in organ culture (Aikawa et al.,
2001). In addition to inducing expression of Cdk inhibitors,
FGF signaling could also induce the expression or the activ-
ity of phosphatases specifically targeting the Rb proteins.
This activity might be particularly relevant to p107, because
p107 appeared to undergo dephosphorylation with kinetics
that were more rapid than was the accumulation of G1 cells
(our unpublished results). In this regard, p107 dephosphor-
ylation has been reported to be rapidly induced by DNA
damaging agents (Voorhoeve et al., 1999; Kondo et al.,
2001), suggesting that rapid p107 dephosphorylation might
similarly be induced in FGF-treated chondrocytes. At this
time, we believe that induction of phosphatases and Cdk in-
hibitors could participate, probably together with other
mechanisms, in producing the profound growth-inhibiting
effect of FGF in chondrocytes.
Materials and methods
Cell culture and proliferation assay
RCS cells were cultured on 100-mm cell culture dishes (Corning Incorpo-
rated) in DME containing 10% FCS. For proliferation assays, cells either
cultivated on glass coverslips or Lab-Tek
® chamber slides (Nunc) were in-
cubated for 3 h with 10  g/ml of BrdU and were fixed with 3.7% PFA. In-
corporation of BrdU into cell DNA was detected by immunofluorescence.
In brief, fixed cells were permeabilized with 0.5% Triton X-100 and subse-
quently treated with 1.5 M HCl. After several washes in PBS, cells were in-
cubated with a mouse anti-BrdU mAb (RPN-202; Amersham Biosciences).
Cy3-conjugated anti–mouse antibody (Jackson ImmunoResearch Laborato-
ries) was used as a secondary antibody. Cell nuclei were counterstained by
incubation with 0.5  g/ml Hoechst (Sigma-Aldrich) before mounting on
slides. Pictures were taken with a microscope (Axioplan 2; Carl Zeiss Mi-
croImaging, Inc.) equipped with a digital camera.
For FACScan™ analysis, trypsinized cells were fixed in 70% ice-cold
ethanol. After centrifugation, the cell pellets were washed with PBS and
treated overnight with 50  g/ml propidium iodide in the presence of 100
 g/ml RNase in order to stain the nuclei. Flow cytometry was performed
using a FACScan™ (Becton Dickinson) equipped with a doublet discrimi-
nation module. Doublets were gated out on a plot of signal area versus sig-
nal width and analyzed using ModFit LT™ (Verity Software House).
For proliferation assays, FACScan™ analysis, and biochemical assays,
RCS cells cultivated in DME containing 10% FCS were treated with recom-
binant human FGF-1 at the indicated concentrations together with 10  g/
ml heparin. Dexamethasone was purchased from Sigma-Aldrich.
Cloning and retroviral infections
PyLT antigen cDNA cloned in the pBabe-Puro retroviral expression vector
was described previously (Mansukhani et al., 2000). This vector contains a
resistance gene for puromycin. Mutant PyLT cDNAs (PyLT- 141–158 and
PyLT- 256–272, a gift from Dr. A. Mes-Masson, McGill University, Mon-
treal, Canada), as well as wild-type E1A and mutant E1A (E1A-12S.928)
cDNAs were subcloned in pBabe-Puro. For retroviral infection, 293T cells
were first transfected by calcium phosphate precipitation method by mix-
ing equal amounts of retroviral construct together with helper virus vector
pCL-eco (Naviaux et al., 1996). 48–72 h after transfection, supernatant
was collected and used to infect RCS cells for 16 h in the presence of 10
 g/ml polybrene. Cells were cultivated for two additional days before se-
lection with 2  g/ml puromycin. PyLT- and PyLT- 256–272–expressing
RCS cells were further subcloned and at least two clones of each line were
analyzed.
Immunoprecipitation and Western blotting
Cell lysis was done either in RIPA buffer or immunoprecipitation lysis
buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 0.1% Triton X-100, 1 mM
EDTA) in the presence of a cocktail of protease and phosphatase inhibitors.
For immunoprecipitation assays, 1 mg of total protein extracts was incu-
bated overnight at 4 C with 10  g antibodies. Protein G Plus–Agarose (On-
cogene Research Products) was added the next day for 2 h at 4 C, and the
immune complexes were washed three to four times in immunoprecipita-
tion lysis buffer. Immunoprecipitates and total protein extracts (20  g) were
separated by SDS-PAGE, transferred onto nitrocellulose membranes (Pro-
tran
®; Schleicher & Schuell) and analyzed by ECL detection system (Amer-
sham Biosciences). The following antibodies were used: anti-pRb mAb
(G3–245; BD Biosciences), anti-p107 pAb (C-18; Santa Cruz Biotechnol-
ogy, Inc.), p130 mAb (R27020; Transduction Laboratories), anti-p16, anti-
p18, anti-p21, and anti-p57 pAbs (M-156, N-20, C-19, and H-91, re-
spectively; Santa Cruz Biotechnology, Inc.), anti-p27 mAb (K25020;
Transduction Laboratories), anti-Grb2 mAb (G16720; Transduction Labo-
ratories), anti-PyLT antigen mAb (PN116; a gift from Dr. B. Schaffhausen,
Tufts University Medical School, Boston, MA), anti-FGFR3 pAb (C-15;
Santa Cruz Biotechnology, Inc.), and anti-phosphotyrosine mAb (4G10;
Upstate Biotechnology). HRP-conjugated anti–mouse and anti–rabbit sec-
ondary antibodies were purchased from Promega.
Preparation of chondrocyte micromass cultures
To generate embryos of the desired genotypes, matings were conducted
between p107
 / ;p130
 /  and p107
 / ;p130
 /  mice or by intercrossing
p107
 /  or Rb
 /  mice, and were assumed for timing purposes to occur at
midnight. Micromass cultures were performed as in Edwall-Arvidsson and
Wroblewski (1996) with the following modifications: forelimb and hind-
limb buds were removed from E11.5 embryos and pooled in an Eppendorf
tube. After two washes in PBS, the limbs were centrifuged for 1 min at
3,000 rpm in a microcentrifuge, resuspended in 1 mg/ml collagenase A
(Roche) in Ham’s F12 medium and incubated at 37 C for 1 h. The tissues
were gently triturated to obtain a single cell suspension, washed two times
in Ham’s F12 medium, and resuspended at 0.9   10
6 cells/ml, in Ham’s
F12 medium supplemented with 1% FCS (HyClone). High density (supra-
confluent) micromass cultures were initiated by spotting 20- l drops onto
the surface of tissue culture dishes (6-well dish; Nunc), or onto a coverslip
for experiments requiring confocal microscopy, and incubated at 37 C for
2 h to allow the cells to attach. Ham’s F12 medium containing 1% FCS
and antibiotics was then added to the culture. The medium was changed
after 2 d of culture or just before FGF treatment.
At various times after plating, micromass cultures were washed in PBS
and fixed for 30 min in 4% PFA in PBS. To determine the accumulation of
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1% Alcian blue (Sigma-Aldrich) in 3% acetic acid (Leonard et al., 1991),
and were washed for 6 h in 3% acetic acid.
Confocal microscopy analysis
Micromass cultures were washed in PBS and fixed in 100% methanol. Af-
ter three washes in PBS, the cultures were blocked in 4% horse serum in
PBS for 1 h. Antibodies anti-BrdU (Beckton Dickinson) at 1/100 dilution,
anti–collagen II (Santa-Cruz Biotechnology, Inc.) at 1/100 dilution, or anti-
FGFR3 (sc-123; Santa-Cruz Biotechnology, Inc.) at 1/100 dilution were
added in 4% horse serum in PBS, at 4 C overnight. After three washes with
PBS, the secondary antibodies (anti–mouse Cy3, anti–goat FITC, and anti–
rabbit Cy3; Jackson ImmunoResearch) were added at 1/200 dilution, for
45 min at RT. After three washes with PBS, the nuclei were stained with
DAPI, and the coverslip was mounted on a glass slide with Vectashield
®
(Vector Laboratories). Foci of  20  m diameter were selected and ana-
lyzed over a series of 1  m confocal sections using a confocal laser scan-
ning microscope (model LSM410; Carl Zeiss MicroImaging, Inc.). The per-
centage of BrdU-positive cells was determined by analysis of each
confocal section. The results are a mean of at least five foci for each geno-
type and each condition.
Organ cultures
Metatarsal long bone rudiments from E15 mouse embryo (generated as de-
scribed in the chondrocyte micromass section) heterozygotes or nulls for
the p107 and/or p130 genes were dissected under sterile conditions. The
cartilaginous long bones were left intact. Organ culture medium consisted
of MEM without nucleosides (GIBCO BRL) supplemented with 50  g/ml
ascorbic acid, 300  g/ml L-glutamine, 50  g/ml gentamicine, 250  g/ml
Fungizone, 1 mM  -glycerophosphate, and 0.2% BSA Cohn fraction V
(complete medium; Sigma-Aldrich). Each long bone was cultured individ-
ually in Transwells
® (Costar) containing 400  l of complete medium in the
presence or absence of 100 ng/ml recombinant human FGF-1 and 10  g/
ml heparin. The metatarsal cultures were maintained at 37 C for 48 h. For
the proliferation assays, the long bones were treated with FGF-1 for 24 h
and BrdU (1  g/ml final concentration) was added during the last 6 h of
treatment. The experiments were set up for left/right paired observations,
with one metatarsal serving as a control to the other.
Metatarsals were fixed in 4% PFA overnight at 4 C and embedded in
paraffin, and 4- m tissue sections were performed. Sections were deparaf-
finized by treatment with xylene and rehydrated with successive washes of
100, 95, and 70% ethanol, followed by washes in TS buffer (100 mM Tris-
HCl, pH 7.4, 150 mM NaCl) and permeabilization with 0.25% Triton
X-100. After 3 h of blocking with 3% goat serum, the endogenous peroxi-
dase activity was inactivated by incubating in 5% H2O2 in methanol for 10
min. Anti-BrdU mAb was used with a Vectastain Elite ABC Kit (Vector Lab-
oratories). Preparations were subsequently counterstained with 0.1% Al-
cian blue 8GX in 3% acetic acid. After dehydration, samples were
mounted with Permount
® (Fisher Scientific International).
We wish to thank Lisa Dailey, Alka Mansukhani, and H. Skopicki for advice
and helpful discussion, Milton Gomez for help with the histology prepara-
tions, and Anne Marie Mes-Masson and Paolo Dotto for the gift of plasmids.
This investigation was supported by National Institutes of Health grants
DE13745 (to C. Basilico) and HD35156 (to D. Cobrinik). The Columbia
University Optical Microscopy Facility is supported by grant P30CA13696.
Submitted: 7 May 2002
Revised: 14 June 2002
Accepted: 18 June 2002
References
Ahrens, P.B., M. Solursh, R.S. Reiter, and C.T. Singley. 1979. Position-related ca-
pacity for differentiation of limb mesenchyme in cell culture. Dev. Biol. 69:
436–450.
Aikawa, T., G.V. Segre, and K. Lee. 2001. Fibroblast growth factor inhibits chon-
drocytic growth through induction of p21 and subsequent inactivation of
cyclin E-Cdk2. J. Biol. Chem. 276:29347–29352.
Basilico, C., and D. Moscatelli. 1992. The FGF family of growth factors and onco-
genes. Adv. Cancer Res. 59:115–165.
Clarke, A.R., E.R. Maandag, M. van Roon, N.M. van der Lugt, M. van der Valk,
M.L. Hooper, A. Berns, and H. te Riele. 1992. Requirement for a functional
Rb-1 gene in murine development. Nature. 359:328–330.
Classon, M., and N. Dyson. 2001. p107 and p130: versatile proteins with interest-
ing pockets. Exp. Cell Res. 264:135–147.
Cobrinik, D., M.H. Lee, G. Hannon, G. Mulligan, R.T. Bronson, N. Dyson, E.
Harlow, D. Beach, R.A. Weinberg, and T. Jacks. 1996. Shared role of the
pRB-related p130 and p107 proteins in limb development. Genes Dev. 10:
1633–1644.
Dannenberg, J.H., A. van Rossum, L. Schuijff, and H. te Riele. 2000. Ablation of
the retinoblastoma gene family deregulates G(1) control causing immortal-
ization and increased cell turnover under growth-restricting conditions.
Genes Dev. 14:3051–3064.
De Luca, F., and J. Baron. 1999. Control of bone growth by fibroblast growth fac-
tors. Trends Endocrinol. Metab. 10:61–65.
Deng, C., P. Zhang, J.W. Harper, S.J. Elledge, and P. Leder. 1995. Mice lacking
p21CIP1/WAF1 undergo normal development, but are defective in G1
checkpoint control. Cell. 82:675–684.
Deng, C., A. Wynshaw-Boris, F. Zhou, A. Kuo, and P. Leder. 1996. Fibroblast
growth factor receptor 3 is a negative regulator of bone growth. Cell. 84:
911–921.
Dotto, G.P., L.F. Parada, and R.A. Weinberg. 1985. Specific growth response of ras-
transformed embryo fibroblasts to tumour promoters. Nature. 318:472–475.
Dyson, N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev. 12:
2245–2262.
Dyson, N., R. Bernards, S.H. Friend, L.R. Gooding, J.A. Hassell, E.O. Major,
J.M. Pipas, T. Vandyke, and E. Harlow. 1990. Large T antigens of many
polyomaviruses are able to form complexes with the retinoblastoma protein.
J. Virol. 64:1353–1356.
Edwall-Arvidsson, C., and J. Wroblewski. 1996. Characterization of chondrogene-
sis in cells isolated from limb buds in mouse. Anat. Embryol. (Berl). 193:
453–461.
Ewen, M.E. 1998. Regulation of the cell cycle by the Rb tumor supressor family. In
Cell Cycle Control. M. Pagano, editor. Springer-Verlag, New York. 149–
179.
Goldfarb, M. 1996. Functions of fibroblast growth factors in vertebrate develop-
ment. Cytokine Growth Factor Rev. 7:311–325.
Hannon, G.J., D. Demetrick, and D. Beach. 1993. Isolation of the Rb-related p130
through its interaction with CDK2 and cyclins. Genes Dev. 7:2378–2391.
Hoshikawa, Y., A. Mori, K. Amimoto, K. Iwabe, and M. Hatakeyama. 1998. Con-
trol of retinoblastoma protein-independent hematopoietic cell cycle by the
pRB-related p130. Proc. Natl. Acad. Sci. USA. 95:8574–8579.
Hurford, R.K., Jr., D. Cobrinik, M.H. Lee, and N. Dyson. 1997. pRB and p107/
p130 are required for the regulated expression of different sets of E2F re-
sponsive genes. Genes Dev. 11:1447–1463.
Inada, M., T. Yasui, S. Nomura, S. Miyake, K. Deguchi, M. Himeno, M. Sato, H.
Yamagiwa, T. Kimura, N. Yasui, et al. 1999. Maturational disturbance of
chondrocytes in Cbfa1-deficient mice. Dev. Dyn. 214:279–290.
Jacks, T., A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, and R.A. Wein-
berg. 1992. Effects of an Rb mutation in the mouse. Nature. 359:295–300.
Jux, C., K. Leiber, U. Hugel, W. Blum, C. Ohlsson, G. Klaus, and O. Mehls.
1998. Dexamethasone impairs growth hormone (GH)-stimulated growth by
suppression of local insulin-like growth factor (IGF)-I production and ex-
pression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocri-
nology. 139:3296–3305.
Karsenty, G. 1999. The genetic transformation of bone biology. Genes Dev. 13:
3037–3051.
Kim, I.S., F. Otto, B. Zabel, and S. Mundlos. 1999. Regulation of chondrocyte
differentiation by Cbfa1. Mech Dev. 80:159–170.
Klaus, G., C. Jux, P. Fernandez, J. Rodriguez, R. Himmele, and O. Mehls. 2000.
Suppression of growth plate chondrocyte proliferation by corticosteroids.
Pediatr. Nephrol. 14:612–615.
Kondo, T., H. Higashi, H. Nishizawa, S. Ishikawa, S. Ashizawa, M. Yamada, Z.
Makita, T. Koike, and M. Hatakeyama. 2001. Involvement of pRB-related
p107 protein in the inhibition of S phase progression in response to geno-
toxic stress. J. Biol. Chem. 276:17559–17567.
Lee, E.Y., C.Y. Chang, N. Hu, Y.C. Wang, C.C. Lai, K. Herrup, W.H. Lee, and
A. Bradley. 1992. Mice deficient for Rb are nonviable and show defects in
neurogenesis and haematopoiesis. Nature. 359:288–294.
Leonard, C.M., H.M. Fuld, D.A. Frenz, S.A. Downie, J. Massague, and S.A. New-
man. 1991. Role of transforming growth factor-beta in chondrogenic pat-
tern formation in the embryonic limb: stimulation of mesenchymal conden-
sation and fibronectin gene expression by exogenous TGF-beta and evidence
for endogenous TGF-beta-like activity. Dev. Biol. 145:99–109.
Lipinski, M.M., and T. Jacks. 1999. The retinoblastoma gene family in differentia-
tion and development. Oncogene. 18:7873–7882.750 The Journal of Cell Biology | Volume 158, Number 4, 2002
Mansukhani, A., P. Bellosta, M. Sahni, and C. Basilico. 2000. Signaling by fibro-
blast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-
activating mutations blocks mineralization and induces apoptosis in osteo-
blasts. J. Cell Biol. 149:1297–1308.
Mulligan, G., and T. Jacks. 1998. The retinoblastoma gene family: cousins with
overlapping interests. Trends Genet. 14:223–229.
Naski, M.C., and D.M. Ornitz. 1998. FGF signaling in skeletal development.
Front. Biosci. 3:D781–D794.
Naski, M.C., Q. Wang, J. Xu, and D.M. Ornitz. 1996. Graded activation of fibro-
blast growth factor receptor 3 by mutations causing achondroplasia and tha-
natophoric dysplasia. Nat. Genet. 13:233–237.
Naviaux, R.K., E. Costanzi, M. Haas, and I.M. Verma. 1996. The pCL vector sys-
tem: rapid production of helper-free, high-titer, recombinant retroviruses. J.
Virol. 70:5701–5705.
Pilon, A.A., P. Desjardins, J.A. Hassell, and A.M. Mes-Masson. 1996. Functional
implications of mutations within polyomavirus large T antigen Rb-binding
domain: effects on pRb and p107 binding in vitro and immortalization ac-
tivity in vivo. J. Virol. 70:4457–4465.
Powers, C.J., S.W. McLeskey, and A. Wellstein. 2000. Fibroblast growth factors,
their receptors and signaling. Endocr. Relat. Cancer. 7:165–197.
Rossi, F., H.E. MacLean, W. Yuan, R.O. Francis, E. Semenova, C.S. Lin, H.M.
Kronenberg, and D. Cobrinik. 2002. p107 and p130 coordinately regulate
proliferation, Cbfa1 expression, and hypertrophic differentiation during en-
dochondral bone development. Dev. Biol. 247:271–285.
Sage, J., G.J. Mulligan, L.D. Attardi, A. Miller, S. Chen, B. Williams, E. Theodorou,
and T. Jacks. 2000. Targeted disruption of the three Rb-related genes leads to
loss of G(1) control and immortalization. Genes Dev. 14:3037–3050.
Sahni, M., D.C. Ambrosetti, A. Mansukhani, R. Gertner, D. Levy, and C. Basilico.
1999. FGF signaling inhibits chondrocyte proliferation and regulates bone
development through the STAT-1 pathway. Genes Dev. 13:1361–1366.
Sahni, M., R. Raz, J.D. Coffin, D. Levy, and C. Basilico. 2001. STAT1 mediates
the increased apoptosis and reduced chondrocyte proliferation in mice over-
expressing FGF2. Development. 128:2119–2129.
Sardet, C., M. Vidal, D. Cobrinik, Y. Geng, C. Onufryk, A. Chen, and R.A. Wein-
berg. 1995. E2F-4 and E2F-5, two members of the E2F family, are expressed
in the early phases of the cell cycle. Proc. Natl. Acad. Sci. USA. 92:2403–2407.
Takeda, S., J.P. Bonnamy, M.J. Owen, P. Ducy, and G. Karsenty. 2001. Continu-
ous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its abil-
ity to induce hypertrophic chondrocyte differentiation and partially rescues
Cbfa1-deficient mice. Genes Dev. 15:467–481.
Thomas, D.M., S.A. Carty, D.M. Piscopo, J.S. Lee, W.F. Wang, W.C. Forrester,
and P.W. Hinds. 2001. The retinoblastoma protein acts as a transcriptional
coactivator required for osteogenic differentiation. Mol. Cell. 8:303–316.
Voorhoeve, P.M., R.J. Watson, P.G. Farlie, R. Bernards, and E.W. Lam. 1999.
Rapid dephosphorylation of p107 following UV irradiation. Oncogene. 18:
679–688.
Wang, H.G., Y. Rikitake, M.C. Carter, P. Yaciuk, S.E. Abraham, B. Zerler, and E.
Moran. 1993. Identification of specific adenovirus E1A N-terminal residues
critical to the binding of cellular proteins and to the control of cell growth. J.
Virol. 67:476–488. 
Webster, M.K., and D.J. Donoghue. 1997. FGFR activation in skeletal disorders:
too much of a good thing. Trends Genet. 13:178–182.